Page 5,654«..1020..5,6535,6545,6555,656..5,6605,670..»

Safety And Stem Cell Procedures (last of two parts)

Posted: Published on February 26th, 2013

Stem Cell Therapy is a promising avenue for medicine, with potential as a cure for a host of illnesses and conditions, and is seen as a way to counteract the effects of aging on the human body. As such, it has become the buzzword in social circles, with youthful-looking celebrities being whispered about as having undergone the treatment abroad. Now that there are already several facilities that are offering Stem Cell treatments right here in the country, Dr. Cristina Puyat of the Anti-Aging Sciences & Cosmetic Institute (ASCI) in Pasig City gives a lowdown on what to expect with your "get-well" shots. Prepping for the procedure From the outset, Puyat presents this caveat: "The only stem cells that have been shown to be safe are the stem cells derived from autologous sources (stem cells from the patients themselves). As any medical or experimental procedure carries a risk, patients should be well informed before embarking on any therapy or procedure and discuss concerns with the physician conducting such procedure. At the ASCI, only those patients who are well informed and who qualify for the stem cell treatment may receive such treatment. Comprehensive laboratory results, a thorough history, and a physical must … Continue reading →

Comments Off on Safety And Stem Cell Procedures (last of two parts)

Drogueria Americana, a Honduran Affiliate of GeneCell International, Presents to a Panel of More Than 100 Leading …

Posted: Published on February 26th, 2013

The Future of Regenerative Medicine: Dental Pulp Stem Cells and Dental Pulp Stem Cell Banking MIAMI, Florida (PRWEB) February 25, 2013 GeneCells Director of Research and Laboratory Operations, Dr. Todd Flower, spoke Friday, January 25th, 2013 at 10am, at the Marriott Hotel to a panel of more than 100 leading dentists from Tegucigalpa, Honduras. Media agencies who attended the conference included: Drogueria Americana is the only Dental Pulp (and cord blood) establishment to be offering this cutting-edge, regenerative medicine technology in Honduras. The program was kicked-off with a special introduction by Dr. Yisela Irasema Andino, who welcomed guests and shared her excitement on the companys successful expansion of its services to the Honduran Market. Very much like cord blood, a childs loose tooth, extracted wisdom and/or adult teeth and pulpectomy can provide first-rate stem cells that can potentially be used in cellular-therapy based applications down the road, said GeneCells Director of operations, Jose Cirino. With more than a decade of experience and deep roots in the Latin American community, we are uniquely poised to help families in the U.S., Latin America and the Caribbean make informed decisions regarding how they can preserve stem cells for their long-term health. This opportunity … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Drogueria Americana, a Honduran Affiliate of GeneCell International, Presents to a Panel of More Than 100 Leading …

Acorda Therapeutics to Present at the Cowen & Company 33rd Annual Health Care Conference

Posted: Published on February 25th, 2013

ARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ron Cohen, M.D., Acordas President and Chief Executive Officer, will present at the Cowen & Company 33rd Annual Health Care Conference on Monday, March 4 at 2:10 pm ET at the Marriott Copley Plaza Hotel in Boston. A live audio webcast of the presentation can be accessed under Investor Events in the Investor section of the Acorda website at http://www.acorda.com, or you may use the link: http://wsw.com/webcast/cowen10/acor/ Please log in approximately 5 minutes before the scheduled time of the presentations to ensure a timely connection. Archived versions of this webcast will be available until April 4 on the Investors section of http://www.acorda.com. About Acorda Therapeutics Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with MS, spinal cord injury and other neurological conditions. Acorda markets AMPYRA (dalfampridine) Extended Release Tablets, 10 mg, in the United States as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an improvement in walking speed. AMPYRA is marketed outside the United States as FAMPYRA (prolonged-release fampridine tablets) by Biogen Idec under a licensing agreement from Acorda. AMPYRA … Continue reading →

Posted in Cerebral Palsy Treatment | Comments Off on Acorda Therapeutics to Present at the Cowen & Company 33rd Annual Health Care Conference

A DIFFERENT BEAT: Addressing the needs of disabled children

Posted: Published on February 25th, 2013

So too do children with disabilities. There are specific differences to their special needs and management. The best way to explain this is through examples as we go through the milestones of development. THE TODDLER F is a boy of 4 who has spastic diplegic cerebral palsy. He was born prematurely and had complications during delivery. F is still unable to walk well. His gross motor functions, namely sitting, standing and walking, is delayed. He walks by cruising along furniture or the wall. He has significant spasticity in both legs and when he stands, he tiptoes with knocked knees. He attends physiotherapy sessions regularly and exercises at home too. His parents are seeking treatment to make him walk better. Apart from that, he interacts well with his siblings. However, his communication skills are mildly impaired. He has difficulty completing a sentence but he is able to understand his parents well. Fs therapy focuses on safe and efficient ambulation, the use of orthotics and aids for walking, spasticity management, effective communication and monitoring as well as attempts at catching up with his development. THE SCHOOLING TEENAGER M is a 9-year-old girl who also suffers from spastic diplegic cerebral palsy. She is … Continue reading →

Posted in Cerebral Palsy Treatment | Comments Off on A DIFFERENT BEAT: Addressing the needs of disabled children

Amarantus BioScience and Banyan Biomarkers to Present Poster of MANF Data at The 3rd Annual Traumatic Brain Injury …

Posted: Published on February 25th, 2013

SUNNYVALE, Calif. and ALACHUA, Fla., Feb. 25, 2013 /PRNewswire/ --Amarantus BioScience, Inc. (AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis centered around its patented therapeutic protein MANF, and Banyan Biomarkers, the leader in developing in vitro diagnostic products to detect TBI, today announced that the companies will be making a joint poster presentation March 6-7, 2013 at The 3rd Annual Traumatic Brain Injury (TBI) Conference in Washington, DC (www.tbiconference.com). The poster is entitled "Mesencephalic astrocyte-derived neurotrophic factor (MANF) neuroprotection from necrotic and apoptotic cell death in rat cortical cultures." "MANF significantly inhibited caspase and calpain-mediated cellular processes of cell death and conferred overall neuroprotection in our cellular model systems of TBI," said Dr. Juan Martinez, Director of Scientific Operations at Banyan Biomarkers. "This neuroprotection indicates therapeutic potential based on well-defined biochemical pathway inhibition. We look forward to working with Amarantus to further develop MANF's therapeutic potential in TBI." About Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is a protein that corrects protein misfolding, one of the major causes of apoptosis (Programmed Cell Death). Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) is believed to have broad potential because it is a naturally-occurring protein produced … Continue reading →

Posted in Brain Injury Treatment | Comments Off on Amarantus BioScience and Banyan Biomarkers to Present Poster of MANF Data at The 3rd Annual Traumatic Brain Injury …

Lpath to Present Data at Arrowhead's 3rd Annual Traumatic Brain Injury Conference on March 7, 2013

Posted: Published on February 25th, 2013

SAN DIEGO, CA--(Marketwire - Feb 25, 2013) - Lpath, Inc. ( NASDAQ : LPTN ), the industry leader in bioactive lipid-targeted therapeutics, has been invited to present data from its Lpathomab program in models of central nervous system injury, including traumatic brain injury (TBI), at Arrowhead's 3rd Annual Traumatic Brain Injury Conference. Lpathomab is a first-in-class monoclonal antibody that binds to and neutralizes lysophosphatidic acid (LPA), a bioactive lipid that has been implicated in neuropathic pain, neurotrauma, and various other disorders. Lpath's vice president and founder, Roger Sabbadini, Ph.D., will present at the Sheraton Crystal City Hotel in Washington, DC on March 7, 2013, at 11:15 a.m. Eastern time. He will discuss a study entitled, "Monoclonal Anti-lysophosphatidic Acid Antibodies Are Neuroprotective after Experimental TBI." The study is part of a collaboration between Lpath and scientists at the University of Melbourne (Alice Pebay, Ph.D. and Peter Crack, Ph.D.), UCLA Brain Injury Research Center (Neil Harris, Ph.D.), and University of Kentucky (Andrew Morris, Ph.D.). The presentation will demonstrate that: (i) LPA receptors are increased after human brain injury; (ii) LPA levels are upregulated in the cerebrospinal fluid of TBI patients; (iii) Lpathomab administered systemically (single dose post-injury) in mouse models of TBI … Continue reading →

Posted in Brain Injury Treatment | Comments Off on Lpath to Present Data at Arrowhead's 3rd Annual Traumatic Brain Injury Conference on March 7, 2013

Peace Frogs Launches Multiple Sclerosis Design, “MS Gets on My Nerves"

Posted: Published on February 25th, 2013

MS Gets on My Nerves Aims to Help Raise Awareness About the Top Disabling Disease Among Young Adults in the U.S. Gloucester, Va. (PRWEB) February 25, 2013 Multiple sclerosis (MS) is an unpredictable, often disabling, disease that attacks the central nervous system, according to the U.S. National Multiple Sclerosis Society. More than 400,000 Americans live with MS. We all need to have the strength to find a cure, said Catesby Jones, Peace Frogs founder and president. Thats why Peace Frogs is pleased to release its newest frog design, MS Gets on My Nerves. MS is the number one disabling disease among young adults in the United States, according to the society. The making of the Peace Frogs MS shirt alone illustrated that startling statistic, Jones said. The slogan came from a friend and fan of Peace Frogs who has MS, Jones said. The shirts were printed by a woman living with MS. And every person on the team knows someone with MS. According to the National MS Societys Hampton Roads chapter, located and serving people near the Peace Frogs headquarters in Virginia, MS symptoms range from numbness and tingling to blindness and paralysis. The advancement, severity and specific symptoms of … Continue reading →

Posted in MS Treatment | Comments Off on Peace Frogs Launches Multiple Sclerosis Design, “MS Gets on My Nerves"

Dr. Mark Anderson of Executive Medicine of Texas talks about Hormone Replacement Therapy – Video

Posted: Published on February 25th, 2013

Dr. Mark Anderson of Executive Medicine of Texas talks about Hormone Replacement Therapy http://www.emtexas.com Executive Medicine of Texas is dedicated to providing confidential medical services to busy and high-profile individuals just like you. Some of the services we offer include extensive half-day physical examinations, concierge medicine, inside-out makeovers, and athletic performance evaluations with strategy plans. Our goal is to keep you healthy and vibrant for years to come. We make a difference every day in the lives of our clients. Schedule your appointment now, so we can start making a difference for you. By: ExecutiveMedicine1 … Continue reading →

Posted in Hormone Replacement Therapy | Comments Off on Dr. Mark Anderson of Executive Medicine of Texas talks about Hormone Replacement Therapy – Video

10 Months on Testosterone (Looking Back On Day 1, Moving Out On My Own? Ups

Posted: Published on February 25th, 2013

10 Months on Testosterone (Looking Back On Day 1, Moving Out On My Own? Ups Downs) Please SHARE THIS VIDEO if you found it useful or if you know somebody who is suffering and/or feeling alone. Thank you. MY FIRST VIDEO: http://www.youtube.com MY STORY My name is Noah and on May 18 2011, I had a rare reaction to a vaccine called VIVITROL and consequently spiraled into a major, agitated, suicidal depression with depersonalization. I lost 25 lbs in 4 weeks and was in full panic or near panic for 8 weeks straight mixed with the darkest most painful depression I cold have ever imagined. I immediately could not work and had to move in with my parents who along with many siblings and friends had to watch me 24/7 as I was so suicidal. I was eventually hospitalized. Getting through each day seemed truly unbearable and I knew I would surely die. I have been put on many many different SSRI's SNRI's Tricyclics, Mood stabilizers, anti psychotics, holistic meds, acupuncture and even a form of shock therapy called RTMS. I barely saw any improvement in my condition for a full year. It was decided I had treatment … Continue reading →

Posted in Hormone Replacement Therapy | Comments Off on 10 Months on Testosterone (Looking Back On Day 1, Moving Out On My Own? Ups

KS3:4 Science – Stem Cell Research- The Issue – Video

Posted: Published on February 25th, 2013

KS3:4 Science - Stem Cell Research- The Issue Crown Copyright. Provided by Arts College Limited. artsuk.org Further resources available on http Licensed to Arts College Limited. Licence information available at: artsuk.org Embryonic stem cells and the future of Parkinson's Disease. Stephen Cuff is only 39, but he suffers from Parkinson's Disease and it has turned his life upside down. He can no longer look after his two children and basic day-to-day activities like shaving, takes him a long time. Conventional drugs have not been successful for Stephen, leaving him no option but to undergo brain surgery. Stephen's operation is successful, but it doesn't cure him. One potential future cure is embryonic stem (ES) cell therapy. This is being pioneered by the likes of Professor Ian Wilmut, who became famous when he cloned Dolly the sheep. Professor Wilmut introduces us to the concept of stem cells and the science behind them, whilst presenting his opinion of the technology. Alison Davies, the chair of No Less Human, is a wheelchair user who would refuse ES cell therapy if it were available. She offers a different ethical perspective as to why the use of ES cells should not be … Continue reading →

Posted in Stem Cell Research | Comments Off on KS3:4 Science – Stem Cell Research- The Issue – Video

Page 5,654«..1020..5,6535,6545,6555,656..5,6605,670..»